Export Market Tiers Explained: Where a New Exporter Can Realistically Compete
Not every destination market is equally reachable. Tiering by registration burden shows where new supply relationships actually start.
Destination regulators, not Indian ones, set the real timeline for market entry. Grouping markets by registration burden — rather than treating 'export to the world' as one undifferentiated goal — is the most useful way to plan a realistic supply strategy.
Tier 1 — Highly regulated
The United States, EU, UK, Japan, Canada, Australia and Switzerland require a USFDA- or EU-GMP-inspected facility and a multi-year, high-cost dossier process (ANDA in the US, MAA/decentralised procedure in the EU) for finished formulations. WHO-GMP alone does not qualify a product for these markets. The realistic route in is API supply backed by a US DMF or EU CEP, or a distribution relationship with an already-approved manufacturer — not direct finished-dose registration as a new exporter.
Tier 2 — Semi-regulated
Brazil, Mexico, Russia, Turkey, South Africa, Saudi Arabia, the UAE and South Korea generally accept a WHO-GMP and COPP dossier, though several conduct their own plant inspection, and a local agent or legal representative is typically mandatory. Timelines run 12–36 months per product — a realistic year-two or year-three market once documentation processes are established.
Tier 3 — Emerging markets
Nigeria, Kenya, Tanzania, Ghana, Uganda, Ethiopia, the Philippines, Vietnam, Myanmar, Cambodia, Sri Lanka, Nepal and several Central American and Andean markets accept a lighter CTD-lite dossier alongside a COPP and free-sale certificate, typically in 4–18 months. WHO Prequalification unlocks donor-funded tender procurement on top of standard registration. This is the recommended starting tier for a new exporter, buying the categories India is strongest in — ARVs, antimalarials, anti-TB medicines, antibiotics and essential-medicine generics.
Tier 0 — No drug registration at all
Nutraceuticals, AYUSH, cosmetics and Class A medical devices require a food-supplement or device notification rather than drug approval in most markets, generally resolved in weeks rather than months. This is the one category where genuine direct-to-consumer e-commerce is legal — Amazon, Shopify and similar channels are viable — though we run it through the same B2B-style bulk-supply model as the rest of the catalogue.